Daiichi Sankyo Launches Anti-Influenza Inavir(R) Inhaler

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 (Public Relations) +81-3-6225-1125 (Investor Relations) http://www.daiichisankyo.com/ Daiichi Sankyo Launches Anti-Influenza Inavir(R) Inhaler Tokyo, Japan (October 19, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced the launch of its anti-influenza treatment Inavir® Dry Powder Inhaler 20mg (generic name, laninamivir octanoate; approval for manufacture and marketing, September 10, 2010; drug price listing, October 4, 2010). Inavir® is a long-acting neuraminidase inhibitor with therapeutic efficacy after a single dosage developed by Daiichi Sankyo. Inavir® shows the same efficacy with a single dose as a five-day administration of oseltamivir. As a new treatment option for influenza, Daiichi Sankyo is confident that Inavir® will be an important alternative for treating influenza, both benefiting patients and contributing to society. In order to prepare for this year's flu season Daiichi Sankyo plans to supply 2 million units of the treatment (40mg) by the end of December 2010 and 4 million units (40mg) by the end of March 2011. Daiichi Sankyo has a solid record in developing and selling antibacterial agents, and also offers influenza vaccines. The addition of Inavir® will further strengthen the company’s lineup for preventing and treating infectious diseases. Product outline (Launch date: October 19, 2010) Product name INAVIR®DRY POWDER INHALER 20mg Generic name laninamivir octanoate ( International Nonproprietary Name) Drug price INAVIR® DRY POWDER INHALER 20mg: ￥2,080.50 per inhaler (Japan standard drug price listing received October 4, 2010) Efficacy Treatment for influenza A and influenza B viruses Dosage Adults: A single inhaled dose of 40 mg of laninamivir octanoate hydrate Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate hydrate. If 10 years old or older, a single inhaled dose of 40 mg of laninamivir octanoate hydrate. Approval for manufacture and marketing September 10, 2010 Remarks Manufacture and marketing: DAIICHI SANKYO Co., Ltd. End

The release as fetched from its publisher. daiichisankyo.com ↗